Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma

• Status: Recruiting
• Trial end date: 2025-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This research study is studying a drug as a possible treatment for High Grade Meningioma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Tiantan Hospital

Criteria

Inclusion Criteria:

• Pathologically diagnosed as a patient with WHO grade III recurrent meningioma

• Age ≥ 18 years

• Kps≥70

• able to accept second surgery

• ECOG Performance Status < 2

• Glucocorticoid dosage dexamethasone ≤5mg/ day or equivalent dose

Exclusion Criteria:

• Participants who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days of protocol treatment, or those who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlier.

• Participants who are receiving any other investigational agents.

• Participants who have a diagnosis of an immunodeficiency.

• Requires treatment with high dose systemic corticosteroids defined as dexamethasone >2mg/day or bioequivalent within 7 days of initiating therapy.

• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent. Unable to undergo brain MRI.